Precigen (PGEN)
NASDAQ:PGEN
Top Page
Precigen
(NASDAQ:PGEN)
Select Model
Select Model
Rating:53Neutral
Price Target:
$4.00
▲(2.83% Upside)
Action:ReiteratedDate:03/27/26
The score is held back primarily by weak financial performance (large losses, persistent cash burn, and increased leverage). The latest earnings call provides the main offset, highlighting accelerating commercialization and near-term revenue momentum, while technicals are mixed and valuation is constrained by ongoing losses and no dividend.
Positive Factors
FDA full approval & durable data
Full FDA approval with a broad label and multi‑year durable response data materially lowers regulatory and adoption risk. Durable clinical outcomes and guideline endorsement help sustain demand, support formulary decisions, and shorten payer contracting timelines over the next 2–6 months.
Negative Factors
Elevated leverage
Sharp increase in leverage meaningfully reduces financial flexibility and raises refinancing risk. A thinner equity cushion limits the company’s ability to absorb setbacks or fund further R&D/commercial expansion without incurring higher funding costs or dilution over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA full approval & durable data
Full FDA approval with a broad label and multi‑year durable response data materially lowers regulatory and adoption risk. Durable clinical outcomes and guideline endorsement help sustain demand, support formulary decisions, and shorten payer contracting timelines over the next 2–6 months.
Read all positive factors
Precigen (PGEN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.38B
Dividend YieldN/A
Average Volume (3M)4.18M
Price to Earnings (P/E)―
Beta (1Y)1.93
Revenue Growth59.20%
EPS Growth-155.65%
CountryUS
Employees143
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.07
Shares Outstanding353,824,500
10 Day Avg. Volume3,023,162
30 Day Avg. Volume4,183,657
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)60.91
Price to Sales (P/S)131.52
P/FCF Ratio-14.50
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue118.09
Enterprise Value/Gross Profit318.71
Enterprise Value/Ebitda-4.63
Forecast
1Y Price Target
$9.50Price Target Upside144.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$98.61M
Precigen Business Overview & Revenue Model
Company Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive a...
How the Company Makes Money
Precigen’s revenue is primarily generated through (1) collaboration and licensing arrangements and (2) product-related revenue if/when any therapeutic candidates are approved and commercialized. For collaboration and licensing, the company can ear...
Precigen Earnings Call Summary
Earnings Call Date:Mar 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Positive
The call conveyed strong, tangible commercial momentum driven by full FDA approval and an accelerating launch: substantive payer coverage (≈215M lives, ~90% of insured lives), rapid growth in the patient hub (>300 patients), and an aggressive Q1 revenue expectation (> $18M) support a positive commercial inflection. These positives are balanced against large historical net losses ($429.6M in 2025), a significant SG&A increase (69.8%) tied to the launch, limited product revenue in 2025 due to a late-quarter start, and operational execution risks (conversion timing, EMA timeline, gross-to-net pressure). Overall, the highlights around product approval, payer uptake, and early demand materially outweigh the financial and operational challenges disclosed, leading to a constructive outlook for the company’s commercial transition.Positive Updates
Strong Early Commercial Ramp and Q1 Revenue Guidance
Net product revenue for Q4 2025 was $3.4 million (shipments began in November 2025). Management expects Q1 2026 product revenue to exceed $18.0 million (first full quarter of commercial sales), signaling a rapid ramp in uptake.
Negative Updates
Large Reported Net Loss for 2025
Net loss attributable to common shareholders was $429.6 million, or $1.37 per share, for the year ended 12/31/2025. The results included $318.5 million ($1.02 per share) of large noncash preferred stock/warrant-related items that management says will not recur.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Early Commercial Ramp and Q1 Revenue Guidance
Net product revenue for Q4 2025 was $3.4 million (shipments began in November 2025). Management expects Q1 2026 product revenue to exceed $18.0 million (first full quarter of commercial sales), signaling a rapid ramp in uptake.
Read all positive updates
Company Guidance
Management guided that first-quarter 2026 revenue from the newly approved adult RRP therapy is expected to exceed $18 million (they do not plan to give routine revenue guidance going forward); this follows Q4 2025 net product revenue of $3.4 million (shipments began in November) and total 2025 revenue of $9.7 million versus $3.2 million in 2024 (a 149% increase). Key launch metrics cited included >300 patients in the company hub (versus >200 in mid‑January), payer coverage rising from ~170M to ~215M lives (about 90% of U.S. insured lives), an April 1 permanent J‑code, an expected gross‑to‑net in the high‑teens to low‑twenties percent, and an approximate channel mix of 60–65% commercial; financials noted a 2025 net loss of $429.6M ($1.37/share) including $318.5M ($1.02/share) of noncash items, year‑end cash and investments of $100.4M, and an expectation that cash plus anticipated product sales will fund operations to cash‑flow breakeven by 2026.Precigen Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.68M | 3.92M | 6.22M | 26.91M | 14.27M |
| Gross Profit | 3.59M | -342.00K | 106.00K | 20.57M | -39.41M |
| EBITDA | -106.60M | -123.50M | -89.23M | -62.43M | -77.64M |
| Net Income | -429.64M | -126.23M | -95.90M | 28.32M | -92.17M |
Balance Sheet | |||||
| Total Assets | 156.62M | 145.27M | 151.04M | 215.98M | 359.86M |
| Cash, Cash Equivalents and Short-Term Investments | 97.86M | 97.91M | 62.85M | 55.95M | 108.66M |
| Total Debt | 5.12M | 5.50M | 7.10M | 51.42M | 190.07M |
| Total Liabilities | 135.71M | 106.75M | 32.55M | 89.72M | 252.51M |
| Stockholders Equity | 20.91M | 38.51M | 118.50M | 126.26M | 107.35M |
Cash Flow | |||||
| Free Cash Flow | -87.83M | -76.76M | -68.47M | -69.97M | -63.02M |
| Operating Cash Flow | -87.83M | -68.17M | -66.93M | -65.05M | -55.77M |
| Investing Cash Flow | -1.53M | -20.71M | -3.09M | 226.42M | -74.54M |
| Financing Cash Flow | 90.05M | 110.58M | 29.59M | -155.29M | 121.19M |
Precigen Technical Analysis
Positive
3.89
Price Trends
4.08
Negative
4.07
Negative
3.44
Positive
Market Momentum
-0.20
Negative
55.98
Neutral
30.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PGEN, the sentiment is Positive. The current price of 3.89 is above the 20-day moving average (MA) of 3.43, below the 50-day MA of 4.08, and above the 200-day MA of 3.44, indicating a neutral trend. The MACD of -0.20 indicates Negative momentum. The RSI at 55.98 is Neutral, neither overbought nor oversold. The STOCH value of 30.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PGEN.
Precigen Risk Analysis
Precigen disclosed 61 risk factors in its most recent earnings report. Precigen reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Precigen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $585.35M | 20.60 | 21.24% | ― | 14.77% | -58.90% | |
67 Neutral | $8.43B | -21.87 | -58.74% | ― | 364.98% | -25.33% | |
57 Neutral | $1.24B | ― | -38.79% | ― | ― | 4.29% | |
53 Neutral | $1.38B | -2.96 | -8396.72% | ― | 59.20% | -155.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $2.31B | -8.83 | -57.61% | ― | -4.44% | 63.58% | |
47 Neutral | $1.17B | -14.03 | -84.99% | ― | 103.75% | 33.84% |
* Healthcare Sector Average
PGEN
Precigen
3.89
2.25
137.20%
MDXG
MiMedx Group
3.94
-3.80
-49.10%
WVE
Wave Life Sciences
6.20
-2.81
-31.19%
ORIC
Oric Pharmaceuticals
12.38
6.09
96.82%
IMNM
Immunome
20.41
13.13
180.36%
PRAX
Praxis Precision Medicines
302.69
263.84
679.12%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.